Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (34) 34
humans (34) 34
middle aged (32) 32
oncology (29) 29
adult (28) 28
aged (28) 28
index medicus (26) 26
breast cancer (25) 25
chemotherapy (21) 21
cancer (19) 19
prognosis (18) 18
paclitaxel (15) 15
research (15) 15
treatment outcome (15) 15
breast neoplasms - drug therapy (14) 14
breast neoplasms - pathology (14) 14
immunohistochemistry (14) 14
medicine (13) 13
research article (13) 13
young adult (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
clinical trials (12) 12
breast neoplasms - genetics (10) 10
neoplasm staging (10) 10
carcinoma (9) 9
chemotherapy, adjuvant (9) 9
genetic aspects (9) 9
health aspects (9) 9
hospitals (9) 9
ovarian cancer (9) 9
receptor, erbb-2 - metabolism (9) 9
aged, 80 and over (8) 8
anthracyclines (8) 8
breast neoplasms - mortality (8) 8
disease-free survival (8) 8
epirubicin (8) 8
genetics (8) 8
medical research (8) 8
trastuzumab (8) 8
analysis (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
biomarkers, tumor - metabolism (7) 7
care and treatment (7) 7
dense sequential chemotherapy (7) 7
drug therapy (7) 7
mutation (7) 7
oncology, experimental (7) 7
paclitaxel - administration & dosage (7) 7
patients (7) 7
randomized phase-iii (7) 7
risk factors (7) 7
studies (7) 7
therapy (7) 7
tumors (7) 7
breast (6) 6
breast neoplasms - metabolism (6) 6
cancer patients (6) 6
erbb-2 protein (6) 6
expression (6) 6
fluorouracil - administration & dosage (6) 6
gene expression regulation, neoplastic (6) 6
kaplan-meier estimate (6) 6
multidisciplinary sciences (6) 6
pathology (6) 6
proportional hazards models (6) 6
retrospective studies (6) 6
rna, messenger - genetics (6) 6
rna, messenger - metabolism (6) 6
science (6) 6
adjuvant treatment (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
cancer research (5) 5
cancer therapies (5) 5
cyclophosphamide (5) 5
drug administration schedule (5) 5
drug dosages (5) 5
estrogen-receptor (5) 5
gene amplification (5) 5
genes (5) 5
greece (5) 5
male (5) 5
multivariate analysis (5) 5
product development (5) 5
protein expression (5) 5
receptor, erbb-2 - genetics (5) 5
survival (5) 5
taxanes (5) 5
tissue microarrays (5) 5
adjuvant chemotherapy (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - therapeutic use (4) 4
biomarkers (4) 4
biomarkers, tumor - genetics (4) 4
breast neoplasms - diagnosis (4) 4
breast tumors (4) 4
cancer treatment (4) 4
cancers and neoplasms (4) 4
carboplatin - administration & dosage (4) 4
cooperative oncology group (4) 4
cyclophosphamide - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer
by Lazaridis, G and Kotoula, V and Vrettou, E and Kostopoulos, I and Manousou, K and Papadopoulou, K and Giannoulatou, E and Bobos, M and Sotiropoulou, M and Pentheroudakis, G and Efstratiou, I and Papoudou-Bai, A and Psyrri, A and Christodoulou, C and Gogas, H and Koutras, A and Timotheadou, E and Pectasides, D and Zagouri, F and Fountzilas, G
CANCER GENOMICS & PROTEOMICS, ISSN 1109-6535, 05/2019, Volume 16, Issue 3, pp. 195 - 206
Background/Aim: PTEN-loss and PIK3CA mutations have been addressed as markers of PI3K activation in breast cancer. We evaluated these markers in early... 
adjuvant chemotherapy | PTEN immunohistochemistry | ACTIVATION | MARKER | PHOSPHATASE | discordance | heterogeneity | CHEMOTHERAPY | trastuzumab | LAPATINIB | BENEFIT | HER2-positive breast cancer | ONCOLOGY | PATHWAY | GENETICS & HEREDITY | RESISTANCE | PI3K pathway | EXPRESSION | Carcinoma, Ductal, Breast - genetics | Carcinoma, Lobular - pathology | Receptors, Estrogen - metabolism | Class I Phosphatidylinositol 3-Kinases - genetics | Prognosis | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Neoplasm Recurrence, Local - drug therapy | Receptors, Progesterone - metabolism | Neoplasm Recurrence, Local - pathology | Carcinoma, Ductal, Breast - drug therapy | Carcinoma, Lobular - genetics | Carcinoma, Ductal, Breast - pathology | Female | PTEN Phosphohydrolase - genetics | Survival Rate | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Biomarkers, Tumor - genetics | Carcinoma, Lobular - drug therapy | Mutation | Cohort Studies | Immunohistochemistry | Medical research | Evaluation | Risk groups | Markers | Health risks | Clinical trials | Risk | Breast cancer | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Heterogeneity | Chemotherapy | Breast | PTEN protein | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes
by Mountzios, Giannis and Aivazi, Dimitra and Kostopoulos, Ioannis and Kourea, Helen P and Kouvatseas, George and Timotheadou, Eleni and Zebekakis, Pantelis and Efstratiou, Ioannis and Gogas, Helen and Vamvouka, Chrisanthi and Chrisafi, Sofia and Stofas, Anastasios and Pentheroudakis, George and Koutras, Angelos and Galani, Eleni and Bafaloukos, Dimitrios and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 03/2014, Volume 9, Issue 3, p. e91407
Introduction: We sought to determine the level of protein expression of the critical components of the insulin-like growth factor receptor (IGFR) pathway and... 
COOPERATIVE ONCOLOGY GROUP | MOLECULAR PORTRAITS | POOR SURVIVAL | MULTIDISCIPLINARY SCIENCES | THERAPEUTIC TARGET | PHASE-III | RISK | IGF-1 | FACTOR-I RECEPTOR | TUMORS | ESTROGEN-RECEPTOR | Biomarkers - metabolism | Immunohistochemistry | Reproducibility of Results | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Treatment Outcome | Breast Neoplasms - metabolism | Breast Neoplasms - therapy | Young Adult | Breast Neoplasms - pathology | Receptors, Somatomedin - metabolism | Receptors, Somatomedin - genetics | Adult | Breast Neoplasms - mortality | Female | Aged | Breast Neoplasms - diagnosis | Neoplasm Staging | Medical colleges | Breast cancer | Epidermal growth factor | Analysis | Protein binding | Laboratories | Insulin-like growth factor-binding protein 2 | Estrogen | Clinical trials | Oncology | Insulin-like growth factors | Kinases | Cancer therapies | Subgroups | Critical components | Insulin-like growth factor II receptors | Proteins | Signal transduction | Receptors | Rest | Drug dosages | Medical research | Epidermal growth factor receptors | Gene expression | Insulin | Patients | ErbB-2 protein | Medicine | Studies | Pathology | Chemotherapy | Hospitals | Biomarkers | Breast | Aberration | Molecular biology | Median (statistics) | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
by Fountzilas, George and Kotoula, Vassiliki and Pectasides, Dimitrios and Kouvatseas, George and Timotheadou, Eleni and Bobos, Mattheos and Mavropoulou, Xanthipi and Papadimitriou, Christos and Vrettou, Eleni and Raptou, Georgia and Koutras, Angelos and Razis, Evangelia and Bafaloukos, Dimitrios and Samantas, Epaminontas and Pentheroudakis, George and Skarlos, Dimosthenis V
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e69256
To explore the activity and safety of two schedules of ixabepilone, as first line chemotherapy, in patients with metastatic breast cancer previously treated... 
MICROTUBULE-STABILIZING AGENTS | PLUS CAPECITABINE | EPOTHILONE-B ANALOG | CLINICAL-TRIAL | MESSENGER-RNA EXPRESSION | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | PERIPHERAL NEUROPATHY | PROGESTERONE-RECEPTOR | MISMATCH REPAIR PROTEINS | ESTROGEN-RECEPTOR | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Epothilones - pharmacology | Tubulin - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Epothilones - therapeutic use | RNA, Messenger - metabolism | Epothilones - adverse effects | Neoplasm Metastasis | Tubulin - metabolism | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Adult | Female | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Drug Administration Schedule | RNA, Messenger - genetics | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Epothilones - administration & dosage | Aged | Patient Compliance | Medical research | Care and treatment | RNA | Clinical trials | Breast cancer | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Medicine, Experimental | Product development | Cancer | Schedules | Toxicity | Oncology | Single-nucleotide polymorphism | Neuropathy | Multivariate analysis | Cancer therapies | Metastases | Ovarian cancer | Proteins | Randomization | Safety management | Cell cycle | Peripheral blood | Drug dosages | Deoxyribonucleic acid--DNA | Neutropenia | Markers | FDA approval | Group dynamics | Gene expression | Patients | Survival | ErbB-2 protein | Medicine | Pathology | Hospitals | Tau protein | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
by Pectasides, Dimitrios and Papaxoinis, George and Kalogeras, Konstantine T and Eleftheraki, Anastasia G and Xanthakis, Ioannis and Makatsoris, Thomas and Samantas, Epaminondas and Varthalitis, Ioannis and Papakostas, Pavlos and Nikitas, Nikitas and Papandreou, Christos N and Pentheroudakis, George and Timotheadou, Eleni and Koutras, Angelos and Sgouros, Joseph and Bafaloukos, Dimitrios and Klouvas, George and Economopoulos, Theofanis and Syrigos, Konstantinos N and Fountzilas, George
BMC Cancer, ISSN 1471-2407, 06/2012, Volume 12, Issue 1, pp. 271 - 271
Background: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal... 
Irinotecan | Chemotherapy | Capecitabine | Angiogenic markers | Colorectal cancer | Bevacizumab | COLON-CANCER | OSTEOPONTIN | ONCOLOGY | NITRIC-OXIDE | ORAL FLUOROPYRIMIDINES | BICC-C | EXPRESSION | CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Osteopontin - blood | Leucovorin - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Treatment Outcome | Biomarkers - blood | Angiogenic Proteins - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Care and treatment | Patient outcomes | Research | Comparative analysis | Cancer | Clinical trials | Leucovorin | Metastasis | Antineoplastic agents | Antimitotic agents | Cancer patients | Nitric oxide | Product development | Vascular endothelial growth factor | Growth factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
by Michelle L. Harrison and Eva Obermueller and Nick R. Maisey and Susan Hoare and Kim Edmonds and Ningfeng F. Li and David Chao and Kate Hall and Chooi Lee and Eleni Timotheadou and Kellie Charles and Roger Ahern and D. Mike King and Tim Eisen and Robert Corringham and Mark DeWitte and Frances Balkwill and Martin Gore
Journal of Clinical Oncology, ISSN 0732-183X, 10/2007, Volume 25, Issue 29, pp. 4542 - 4549
Purpose Tumor necrosis factor alpha (TNF-alpha) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an... 
INTERFERON-ALPHA | NETWORK | THERAPY | ONCOLOGY | ANTIBODY | OVARIAN | TNF-ALPHA | THALIDOMIDE | INTERLEUKIN-6 | CANCER | ENDOTHELIAL GROWTH-FACTOR | Tumor Necrosis Factor-alpha - metabolism | Anti-Inflammatory Agents - pharmacology | Antibodies, Monoclonal - pharmacology | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Male | Treatment Outcome | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Chemokine CCL2 - blood | Carcinoma, Renal Cell - metabolism | Infliximab | Antibodies, Monoclonal - administration & dosage | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Aged | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - drug therapy | Interleukin-6 - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
by Fountzilas, George and Valavanis, Christos and Kotoula, Vassiliki and Eleftheraki, Anastasia G and Kalogeras, Konstantine T and Tzaida, Olympia and Batistatou, Anna and Kronenwett, Ralf and Wirtz, Ralph M and Bobos, Mattheos and Timotheadou, Eleni and Soupos, Nikolaos and Pentheroudakis, George and Gogas, Helen and Vlachodimitropoulos, Dimitrios and Polychronidou, Genovefa and Aravantinos, Gerasimos and Koutras, Angelos and Christodoulou, Christos and Pectasides, Dimitrios and Arapantoni, Petroula
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 10 - 10
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with... 
Mrna expression | Anthracyclines | Gene amplification | Top2a | Randomized study | Cish | Early breast cancer | Taxanes | Her2 | TOP2A | early breast cancer | PREDICTIVE MARKERS | MEDICINE, RESEARCH & EXPERIMENTAL | CISH | TOPOISOMERASE-II-ALPHA | taxanes | IN-SITU HYBRIDIZATION | QUANTITATIVE PCR | ESTROGEN-RECEPTOR | mRNA expression | PARAFFIN-EMBEDDED TISSUE | MESSENGER-RNA | PROTEIN EXPRESSION | CELL-CYCLE | anthracyclines | HER2 | gene amplification | randomized study | Multivariate Analysis | Receptors, Estrogen - metabolism | Antibiotics, Antineoplastic - pharmacology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ki-67 Antigen - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Paraffin Embedding | Young Adult | Poly-ADP-Ribose Binding Proteins | Breast Neoplasms - enzymology | Antigens, Neoplasm - metabolism | Adult | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Tissue Fixation | Genes, Neoplasm - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | RNA, Messenger - genetics | Risk Factors | Proportional Hazards Models | Treatment Outcome | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Breast Neoplasms - pathology | Epirubicin - therapeutic use | DNA Topoisomerases, Type II - genetics | Aged | Epirubicin - pharmacology | Genes | Physiological aspects | Breast cancer | Genetic aspects | Research | Epirubicin | Drug therapy | Health aspects | DNA topoisomerase II | Medical research | Oncology | Cytotoxicity | Cancer therapies | Manuscripts | Medicine | Pathology | Chemotherapy | Hospitals | Writing | Drug dosages | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text New agents targeting angiogenesis in glioblastoma
by Timotheadou, Eleni
Chemotherapy research and practice, ISSN 2090-2107, 2011, Volume 2011, pp. 878912 - 8
Glioblastoma is the most common malignant glioma in adults, and despite recent advances in standard treatment, the prognosis still remains dismal, with a... 
Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: A pooled analysis of four prospective adjuvant trials
by Kotoula, Vassiliki and Chatzopoulos, Kyriakos and Lakis, Sotiris and Alexopoulou, Zoi and Timotheadou, Eleni and Zagouri, Flora and Pentheroudakis, George and Gogas, Helen and Galani, Eleni and Efstratiou, Ioannis and Zaramboukas, Thomas and Koutras, Angelos and Aravantinos, Gerasimos and Samantas, Epaminontas and Psyrri, Amanda and Kourea, Helen and Bobos, Mattheos and Papakostas, Pavlos and Kosmidis, Paris and Pectasides, Dimitrios and Fountzilas, George
Oncotarget, ISSN 1949-2553, 2016, Volume 7, Issue 4, pp. 5074 - 5087
Tumor infiltrating lymphocytes (TILs) are considered in the prognosis of breast cancer (BC) patients. Here, we investigated the prognostic/predictive effect of... 
Breast cancer | Clinical breast cancer subtypes | Tumor infiltrating lymphocytes | Prognostic | Trastuzumab | Meta-Analysis as Topic | Prognosis | Prospective Studies | Biomarkers, Tumor - analysis | Breast Neoplasms - immunology | Humans | Survival Rate | Multicenter Studies as Topic | Neoplasm Grading | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Neoplasm Staging | Lymphocytes, Tumor-Infiltrating - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract 538: A role for mutated hydrophobic amino acids in patients with triple-negative breast cancer
by Kotoula, Vassiliki and Lakis, Sotiris and Papadopoulou, Kyriaki and Vlachos, Ioannis and Giannoulatou, Eleni and Alexopoulou, Zoi and Timotheadou, Eleni and Efstratiou, Ioannis and Zagouri, Flora and Pentheroudakis, George and Gogas, Helen and Miliaras, Spyros and Sotiropoulou, Maria and Zografos, George and Pectasides, Dimitrios and Fountzilas, George
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 538 - 538
Background - Aim: Nodal status and stromal tumor infiltrating lymphocyte (TILs) density are independently associated with patient outcome in triple-negative... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group
by Skarlos, Dimosthenis V and Timotheadou, Eleni and Galani, Eleni and Samantas, Epaminondas and Grimani, Irene and Lianos, Evangelos and Aravantinos, Gerasimos and Xanthakis, Ioannis and Pentheroudakis, George and Pectasides, Dimitrios and Fountzilas, George
Oncology, ISSN 0030-2414, 08/2008, Volume 77, Issue 2, pp. 107 - 112
Objective: Recombinant human granulocyte-colony-stimulating factors such as filgrastim and pegfilgrastim have been employed as primary and secondary... 
Clinical Study | Pegfilgrastim | Breast cancer | Dose-dense chemotherapy | Febrile neutropenia | MULTICENTER | COLONY-STIMULATING FACTOR | SINGLE-ADMINISTRATION PEGFILGRASTIM | SEQUENTIAL CHEMOTHERAPY | PHASE-III | PACLITAXEL | CYTOTOXIC CHEMOTHERAPY | EPIRUBICIN | ONCOLOGY | LEUKEMIA | DAILY FILGRASTIM | Neutropenia - epidemiology | Polyethylene Glycols | Humans | Middle Aged | Recombinant Proteins | Fever - epidemiology | Granulocyte Colony-Stimulating Factor - therapeutic use | Breast Neoplasms - drug therapy | Case-Control Studies | Filgrastim | Incidence | Dose-Response Relationship, Drug | Chemotherapy, Adjuvant - adverse effects | Neutropenia - prevention & control | Adult | Female | Fever - prevention & control | Aged | Clinical trials | Chemotherapy | Blood diseases | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study
by Fostira, Florentia and Tsitlaidou, Marianthi and Papadimitriou, Christos and Pertesi, Maroulio and Timotheadou, Eleni and Stavropoulou, Alexandra V and Glentis, Stavros and Bournakis, Evangelos and Bobos, Mattheos and Pectasides, Dimitrios and Papakostas, Pavlos and Pentheroudakis, George and Gogas, Helen and Skarlos, Pantelis and Samantas, Epaminontas and Bafaloukos, Dimitrios and Kosmidis, Paris A and Koutras, Angelos and Yannoukakos, Drakoulis and Konstantopoulou, Irene and Fountzilas, George
Breast Cancer Research and Treatment, ISSN 0167-6806, 7/2012, Volume 134, Issue 1, pp. 353 - 362
In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of... 
Oncology | Hereditary breast–ovarian cancer | BRCA1 | Genetic testing | Medicine & Public Health | Triple-negative breast cancer | Hereditary breast-ovarian cancer | GENOMIC REARRANGEMENTS | FOUNDER MUTATIONS | ESTROGEN-RECEPTOR | PACLITAXEL | EPIRUBICIN | ONCOLOGY | RANDOMIZED PHASE-III | GERMLINE MUTATIONS | DENSE SEQUENTIAL CHEMOTHERAPY | YOUNG-WOMEN | CMF | Carcinoma, Ductal, Breast - genetics | Receptors, Estrogen - metabolism | Carcinoma, Ductal, Breast - epidemiology | Genetic Testing | Prevalence | Hereditary Breast and Ovarian Cancer Syndrome - diagnosis | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Carcinoma, Lobular - epidemiology | Hereditary Breast and Ovarian Cancer Syndrome - metabolism | Patient Selection | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Lobular - genetics | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Carcinoma, Ductal, Breast - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - genetics | Carcinoma, Lobular - diagnosis | Carcinoma, Ductal, Breast - diagnosis | BRCA1 Protein - genetics | Heterozygote | Aged | Carcinoma, Lobular - metabolism | Hereditary Breast and Ovarian Cancer Syndrome - epidemiology | Mutation | BRCA mutations | Oncology, Experimental | Breast cancer | Research | Toy industry | Genetic screening | Prevalence studies (Epidemiology) | Ovarian cancer | Analysis | DNA | Genetic aspects | Diagnosis | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: A Hellenic cooperative oncology group (HeCOG) study
by Papaxoinis, George and Kotoula, Vassiliki and Alexopoulou, Zoi and Kalogeras, Konstantine T and Zagouri, Flora and Timotheadou, Eleni and Gogas, Helen and Pentheroudakis, George and Christodoulou, Christos and Koutras, Angelos and Bafaloukos, Dimitrios and Aravantinos, Gerasimos and Papakostas, Pavlos and Charalambous, Elpida and Papadopoulou, Kyriaki and Varthalitis, Ioannis and Efstratiou, Ioannis and Zaramboukas, Thomas and Patsea, Helen and Scopa, Chrisoula D and Skondra, Maria and Kosmidis, Paris and Pectasides, Dimitrios and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0140293
Background The PI3K-AKT pathway is frequently activated in breast cancer. PIK3CA mutations are most frequently found in the helical (exon 9) and kinase (exon... 
ANDROGEN RECEPTOR | PTEN LOSS | TRASTUZUMAB | SIGNALING PATHWAY | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | TENSIN HOMOLOG | DENSE SEQUENTIAL CHEMOTHERAPY | ASSOCIATION | PACLITAXEL | Gene mutations | Adjuvant treatment | Physiological aspects | Breast cancer | Genetic aspects | Research | Drug therapy | Cancer | Immunohistochemistry | Statistical analysis | Carcinoma | Clinical trials | AKT protein | Histology | Statistical methods | Insulin-like growth factors | Kinases | Patients | ErbB-2 protein | Subgroups | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Biomarkers | Breast | Sampling methods | Mutation | PTEN protein | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group
by Psyrri, Amanda and Kalogeras, Konstantine T and Wirtz, Ralph M and Kouvatseas, George and Karayannopoulou, Georgia and Goussia, Anna and Zagouri, Flora and Veltrup, Elke and Timotheadou, Eleni and Gogas, Helen and Koutras, Angelos and Lazaridis, Georgios and Christodoulou, Christos and Pentheroudakis, George and Economopoulou, Panagiota and Laskarakis, Apostolos and Arapantoni-Dadioti, Petroula and Batistatou, Anna and Sotiropoulou, Maria and Aravantinos, Gerasimos and Papakostas, Pavlos and Kosmidis, Paris and Pectasides, Dimitrios and Fountzilas, George
Journal of Translational Medicine, ISSN 1479-5876, 02/2017, Volume 15, Issue 1, p. 30
Background: The shift towards an earlier diagnosis of breast cancer (BC) highlights the need for biomarkers that would identify patients at risk for relapse... 
Prognostic value | IHC | Osteopontin | Breast cancer | MRNA | Survival | QRT-PCR | MEDICINE, RESEARCH & EXPERIMENTAL | MESSENGER-RNA EXPRESSION | qRT-PCR | TISSUE MICROARRAYS | mRNA | PACLITAXEL | SPECIMENS | EPIRUBICIN | RECOMMENDATIONS | RANDOMIZED PHASE-III | PROTEIN EXPRESSION | GROWTH | DENSE SEQUENTIAL CHEMOTHERAPY | Osteopontin - genetics | Multivariate Analysis | Prognosis | Humans | Middle Aged | RNA, Messenger - genetics | Gene Expression Regulation, Neoplastic | Proportional Hazards Models | Osteopontin - metabolism | RNA, Messenger - metabolism | Disease-Free Survival | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Female
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights